{"transactions":[{"id":142735,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":2794,"kind":"organization","name":"ELI LILLY & Co","symbol":"LLY","position":1,"cik":"0000059478","reported_name":"LILLY ELI & CO","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12305,"kind":"organization","name":"ProCar Acquisition Corp","position":2,"cik":"0001695312","reported_name":"ProCar Acquisition Corp","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2017-03-01T22:02:45.000Z","date":"2017-03-01","kind":"other","acquired":true,"shares":19285108,"price":46.5,"value":896757522.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On March 1, 2017, Eli Lilly and Company (\"Parent\") and ProCar Acquisition Corporation (\"Merger Sub\") completed the transactions contemplated by the Agreement and Plan of Merger, dated as of January 17, 2017, by and among CoLucid Pharmaceuticals, Inc. (the \"Issuer\"), Parent and Merger Sub (the \"Merger Agreement\").  Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent (the \"Surviving Corporation\").  At the effective time of the Merger, the outstanding shares of common stock of Merger Sub were converted into and became shares of the Surviving Corporation."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 1, 2017, Eli Lilly and Company (\"Parent\") and ProCar Acquisition Corporation (\"Merger Sub\") completed the transactions contemplated by the Agreement and Plan of Merger, dated as of January 17, 2017, by and among CoLucid Pharmaceuticals, Inc. (the \"Issuer\"), Parent and Merger Sub (the \"Merger Agreement\").  Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent (the \"Surviving Corporation\").  At the effective time of the Merger, the outstanding shares of common stock of Merger Sub were converted into and became shares of the Surviving Corporation."},{"field":"shares","element":"transactionShares","label":"F1","text":"On March 1, 2017, Eli Lilly and Company (\"Parent\") and ProCar Acquisition Corporation (\"Merger Sub\") completed the transactions contemplated by the Agreement and Plan of Merger, dated as of January 17, 2017, by and among CoLucid Pharmaceuticals, Inc. (the \"Issuer\"), Parent and Merger Sub (the \"Merger Agreement\").  Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent (the \"Surviving Corporation\").  At the effective time of the Merger, the outstanding shares of common stock of Merger Sub were converted into and became shares of the Surviving Corporation."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0000899243-17-005803","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/59478/000089924317005803/doc4.xml","form_type":"4"}}]}